View More Recent Stories

Mar 13, 2018 08:00AM BioTime Submits CE Mark Application for European Approval of Renevia®
Mar 7, 2018 08:00AM BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Mar 5, 2018 08:00AM BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
Mar 1, 2018 08:00AM AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
Feb 28, 2018 08:00AM BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
Feb 26, 2018 07:00AM BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
Feb 22, 2018 07:00AM BioTime Appoints Cavan Redmond to Its Board of Directors
Feb 15, 2018 07:00AM Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
Feb 7, 2018 07:00AM BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
Jan 29, 2018 07:00AM Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
Jan 23, 2018 07:00AM BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
Jan 22, 2018 07:00AM BioTime Announces Clinical and Corporate Milestone Targets for 2018
Jan 18, 2018 07:00AM AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
Jan 17, 2018 07:08AM BioTime (BTX) Announces Issuance of 41 New Patents
Jan 17, 2018 07:00AM BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
Jan 5, 2018 04:30PM AgeX Therapeutics to Present at Biotech Showcase Annual Conference
Jan 2, 2018 07:00AM AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
Dec 20, 2017 07:00AM BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
Dec 4, 2017 08:00AM Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference
Dec 4, 2017 07:00AM AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medi
Nov 30, 2017 07:00AM Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference
Nov 15, 2017 08:00AM BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO
Nov 13, 2017 07:00AM BioTime to Participate in Upcoming Conferences
Nov 9, 2017 04:05PM BioTime Reports Third Quarter Results and Recent Corporate Accomplishments
Nov 8, 2017 07:00AM AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London
Oct 26, 2017 07:00AM AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economist’s Conference “The Business of Longevity: Health Innovation for an Ageing World” October 27 in Hong Kong
Oct 24, 2017 07:00AM BioTime to Announce Third Quarter 2017 Results on November 9, 2017
Oct 11, 2017 08:00AM BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
Oct 11, 2017 07:06AM BioTime (BTX), Processa Enter into HyStem Sublicense for Drug Delivery
Oct 11, 2017 07:00AM BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery
Oct 3, 2017 07:00AM BioTime to Present at the Cell and Gene Meeting on the Mesa
Sep 26, 2017 07:03AM BioTime (BTX) Reports Positive Secondary and Additional Positive Long-Term Data from the Renevia Pivotal Trial
Sep 26, 2017 07:00AM BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
Sep 25, 2017 07:00AM BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders
Aug 2, 2017 04:10PM BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Aug 2, 2017 08:42AM BioTime (BTX) Announces AgeX Therapeutics Obtained $10M in Capital
Aug 2, 2017 08:30AM AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
May 10, 2017 04:01PM BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Mar 16, 2017 04:18PM BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Nov 3, 2016 04:01PM BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Aug 9, 2016 04:18PM BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
View More Recent Stories